Back to Newslist May 29 | 2019

Vectron enters non-exclusive collaboration with Mycenax Biotech Inc. to offer a superior and complete solution for microbial production of therapeutic proteins.

Through this agreement, Vectron and Mycenax will assist customers throughout the drug development process, from pre-clinical strain development to commercial manufacture. It combines the best of two worlds, state-of-the-art strain development for modern NBEs and biosimilars with cost-efficient manufacture from an experienced CMO with a great track record.

For more information please see the press release: